Blood thinner clopidogrel fails many seniors – study seeks answers
NCT ID NCT04990596
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at why the blood thinner clopidogrel is less effective in people over 70. Researchers measured levels of the drug's active metabolite and platelet function in 37 patients aged 50 to 100. The goal was to understand how age affects drug resistance, which could lead to safer use in older adults.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- clopidogrel
- What this could lead to
- If successful, this could help explain why clopidogrel is less effective in older adults and point toward better dosing or alternative treatments.
- What could go wrong
- This is a small, completed observational study with only 37 participants, so findings may not apply broadly. It does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
37 people
The number who actually took part.
- Started
-
Jul 2021
- Finished
-
Jan 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
patients from 50 to 100 years treated with clopidogrel 75 mg/d for at least 10 days for primary or secondary prevention of cardiovascular events
- Ages
-
50 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Consecutive patients per 10-year age range, (20 patients per age range from 50 to 100 years included) : * in consultation or hospitalization in one of the participating centres, * treatment with clopidogrel 75 mg/d for at least 10 days for primary or secondary prevention of cardiovascular events. * who have received the information and have not expressed their opposition to participate in the study and who have given their written consent for the performance of genetic examinations and the realization of a biocollection * affiliated to French social security system Exclusion criteria : * treatment with another antithrombotic agent, * myeloproliferative syndrome, * platelet count \< 100 G/L, * acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer, * under dialysis, * no participation in another clinical study, * deprived of liberty
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Drug resistance are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de RENNES
Rennes, France
-
Hôpital Charles Foix
Paris, France
-
Hôpital Européen Georges Pompidou,
Paris, France
-
Hôpital Lariboisière
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.